Skip to main content

Table 5 Expression of RND efflux systems, amino acid substitutions in regulatory genes and antimicrobial susceptibility pattern of 15 A. baumannii isolates with more than four-fold reduction in MIC of at least one antibiotic

From: Characteristics and diversity of mutations in regulatory genes of resistance-nodulation-cell division efflux pumps in association with drug-resistant clinical isolates of Acinetobacter baumannii

Strain

Ward of isolation

Expression level

Amino acid substitutions

AST pattern

AST pattern without PAβN (µg/ml)/fold reduction in MIC with PAβN

adeB

adeG

adeJ

AdeR

AdeS

AdeL

AdeN

BaeS

BaeR

IMP

LVX

FEP

TGC

GEN

ATCC 19,606

–

1

1

1

–

–

–

–

–

–

–

–

–

–

–

–

M2

ICU

2.47

2.53

1.24

H158L

L172P,H189Y,R195G,V235I,S280A,Q281D,Y303F

Q262R

–

S471N,P474S

S40N

XDR

R(32)/–

R(32)/–

R(256)/6

R(8)/–

R(128)/4

M3

ICU

2.56

8.75

2.51

H158L

L172P,H189Y,R195G,V235I,S280A,Q281D,Y303F

Q262R

–

S471N,P474S

S40N

XDR

R(32)/–

R(12)/–

R(256)/6

R(12)/–

R(256)/7

M4

ICU

1.97

0.26

2.11

H158L

L172P,H189Y,R195G,V235I,S280A,Q281D,Y303F

Q262R

–

S471N,P474S

S40N

XDR

R(32)/–

R(32)/–

R(256)/6

R(8)/–

R(256)/5

M9

ICU

10.70

32.89

2.63

I120V,A136V

L172P,G186V,N268H,S280A,Q281D,Y303F

–

–

S437T

–

XDR

R(32)/–

R(32)/4

R(256)/4

R(8)/–

R(256)/6

M20

ICU

9.31

0.09

2.86

D93E, I120V,F132S

S46N, L172P, F214L,I257V,S280A,Q281D,Y303F,I331V

–

–

S471N

–

XDR

R(32)/–

I(4)/–

R(64)/–

R(8)/5

R(256)/–

M23

ICU

10.99

0.04

0.90

D93E, I120V,F132S

S46N, L172P, F214L,I257V, S280A,Q281D, Y303F

–

–

S471N

–

XDR

R(32)/–

I(4)/–

R(256)/4

R(12)/6

R(256)/–

M24

ICU

5.27

3.89

5.85

I120V,A136V

L172P,G186V,N268H,S280A,Q281D,Y303F,N342I

–

–

S437T

–

XDR

R(16)/–

R(8)/–

R(64)/–

R(16)/6

R(16)/–

M29

ICU

1.21

0.008

0.99

D93E, I120V,F132S

S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V

–

–

S471N

–

XDR

R(32)/–

R(12)/–

R(192)/–

R(12)/5

R(256)/–

M30

ICU

1.74

0.002

1.85

D93E, I120V,F132S

S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,N342I

–

–

S471N

–

XDR

R(32)/–

I(4)/–

R(96)/–

R(8)/5

R(256)/–

M31

ICU

0.53

0.22

1.82

H158L

L172P,H189Y,R195G,S280A,Q281D,Y303F,V235I

Q262R

–

S471N,P474S

S40N

XDR

R(32)/–

R(16)/–

R(256)/5

R(16)/–

R(96)/–

M40

ICU

19.69

0.90

2.04

–

L172P,F214L, S280A,Q281D,Y303F

Q262R

–

S471N,P474S

S40N

XDR

R(32)/–

R(8)/–

R(64)/–

R(8)/–

R(256)/–

M42

ICU

16.44

42.51

2.02

–

L172P,F214L, S280A,Q281D,Y303F

Q262R

–

S471N,P474S

S40N

XDR

R(32)/–

R(8)/–

R(64)/–

R(8)/–

R(256)/–

M54

ICU

1.10

0.001

1.75

D93E, I120V,F132S

S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V, N342I

–

–

–

–

XDR

R(32)/–

I(4)/–

R(256)/5

S(2)/–

R(256)/–

M59

ICU

5.09

0.004

0.82

D93E, I120V,F132S

S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V, N342I

–

–

S471N

–

XDR

R(32)/–

I(4)/–

R(256)/5

R(8)/4

R(256)/–

M60

ICU

1.16

0.70

1.74

D93E, I120V,F132S

S46N, L172P, F214L,I257V, S280A,Q281D,Y303F,I331V, N342I

–

–

S471N

–

XDR

R(32)/–

R(32)/–

R(256)/–

I(4)/–

R(256)/5

  1. AST, antimicrobial susceptibility testing; PAβN, phenylalanine-arginine beta-naphthylamide; MIC, minimum inhibitory concentration; IMP, imipenem; LVX, levofloxacin; FEP, cefepime; TGC, tigecycline; GEN, gentamicin